







HADRON THERAPY

Friday 18th, Octomber 2024

Questions for lecturer Ugo Amaldi (TERA Foundation)

(questions for other lecturers can be found in the respective category on the left)







HADRON THERAPY SYMPOSIUM

Questions for Sandro Rossi (CNAO)

1.the carbon gantry in Japan started treating patients yet?

ANSWER: Yes, they did since many years







HADRON THERAPY SYMPOSIUM

Questions for Sara Lillo (CNAO)

1. Have you made any attempt to estimate the lateral energy deposition due to target fragmentation

ANSWER:

Treatment planning systems commonly used in clinical practice optimize the dose calculation by considering the dose deposited by the fragments, even if roughly. For medical physics investigations and scientific research, we can adopt Fluka Monte Carlo code for this specific purpose.









HADRON THERAPY SYMPOSIUM

Questions for Angelica Facoetti (CNAO)







HADRON THERAPY SYMPOSIUM

Questions for Sanja Damjanovic (GSI)









HADRON THERAPY SYMPOSIUM

Questions for Sotirios Charisopoulos (IAEA)





This project has received funding from the European Union's Herizon 2020 research and innovation programme under crant agreement No 101003548



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Manjit Dosanjh







HADRON THERAPY

Questions for Maurizio Vretenar (CERN)

1. Thank you! for so interesting speech.

The topic or alpha or carbon beams is so interesting. may you give some bibliographical references about the advantage and disadvantage of both types of beams?. Radiobiological, facility challenges, etc. Thanks!

ANSWER: Thanks for your interest! The best reference to the recent work on treatment with alpha particles is Andrea Mairani *et al* 2022 *Phys. Med. Biol.* **67** 15TR02, **DOI** 10.1088/1361-6560/ac65d3, accessible under

https://iopscience.iop.org/article/10.1088/1361-6560/ac65d3 . This is the most complete review on the subject, and gives a comparison with carbon ion therapy.





This project has received funding from the European Union's Herizon 2020 research and innovation programme under grant agreement No 101008548



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Emmanuel Tsesmelis (CERN)





This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101003548



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Leandar Litov (Uni Sofia)





This project has received funding from the European Union's Herizon 2020 research and innovation programme under grant agreement No 101003548



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Roberto Orecchia (IEO)









Questions for Konrad Lehmann (GSI)





This project has received funding from the European Union's Herizon 2020 research and innovation programme under grant extrement No. 103003548



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Andrea Mairani (HIT)

1.ANN will be an alternative to Monte Carlo Planning Systems?

ANSWER:





This project has received funding from the European Union's Horizon 2020 research and innovation reagranges wasterness to 101003548.



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Pawel Olko (IFJPAN)





This project has received funding from the European Union's Herizon 2020 research and innovation programme under crant agreement No 101003548



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Angelica Facoetti (CNAO)





This project has received funding from the European Union's Herizon 2020 research and innovation programme under grant agreement No 101008548



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Alessandra Lombardi (CERN)





This project has received funding from the European Union's Herizon 2020 research and innovation programme under grant agreement No 101003548



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Ernesto De Matteis (INFN)





This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008548



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Ariel Haziot (CERN)









HADRON THERAPY SYMPOSIUM

Questions for Aris Mamaras (CERN/AUTH)







HADRON THERAPY SYMPOSIUM

Questions for Amer Ajanovic (CERN/USA) Danis Bradaric ,Naida Ustavdic , Medina Dugonjic (UNSA)









HADRON THERAPY SYMPOSIUM

Questions for Elpida Theodoridou (DKFZ, Uni Malta), Joao Seco (DKFZ, Uni Heidenberg)






This project has received funding from the European Union's Herizon 2020 research and innovation programme under grant agreement No 101008548



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Laura Vallow









HADRON THERAPY SYMPOSIUM

Sturday 19th, Octomber 2024

Questions for Maria Rosaria Fiore (CNAO)







HADRON THERAPY SYMPOSIUM

Questions for Tasos Kyriazoglou (Attikon University Hospital)

1. E. IAKOVAKI: what is the prognosis in intraperitoneal sarcomas and what treatment do you suggest?

ANSWER:









HADRON THERAPY SYMPOSIUM

Questions for Christos Boskos (ST LUKE'S)





This project has received funding from the European Union's Herizon 2020 research and innovation programme under grant agreement No 101008548



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Anna Makridou (THEAGENIO)








Union's Herizon 2020 research and innovation



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Michael D.Story (Mayo Clinic)









HADRON THERAPY SYMPOSIUM

Questions for Arnold Pompos (UTS), Joao Seco (DKFZ)





This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008548



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Lisa Licitra (CNAO, Uni Milan)





This project has received funding from the European Union's Harizon 2020 research and innovation programme under grant agreement No 101003548



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Maria Vittoria Livraga (CNAO)






This project has received funding from the European Union's Herizon 2020 research and innovation programme under grant engagement No. 103003548



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Silvia Meneghello (CNAO)









HADRON THERAPY SYMPOSIUM

Questions for Katerina Zourou(Web2Learn), Stefania Oikonomou (Web2Learn)







HADRON THERAPY SYMPOSIUM

Questions for Alkinoos Athanasiou (AUTH, ELEVIT)




This project has received funding from the European Union's Harizon 2020 research and innovation programme under grant agreement No 101008548



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Menia Koykoygianni (NGO KARKINAKI)









HADRON THERAPY SYMPOSIUM

Questions for Panagiotis Bamidis (AUTH /AHEPA ,ELEVIT)





This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008548



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Sandro Rossi (CNAO)







HADRON THERAPY SYMPOSIUM

Questions for Piero Fossati (MedAustron)









HADRON THERAPY SYMPOSIUM

Questions for Carola Lutgendorf-Caucig (MedAustron)





This project has received funding from the European Union's Harizon 2020 research and innovation programme under grant agreement No 101008548




www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Sabina Vennarini (CNAO)









HADRON THERAPY SYMPOSIUM

Questions for Alfredo Mirandola (CNAO)





This project has received funding from the European Union's Herizon 2020 research and innovation programme under grant agreement No 101008548



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Nikos Foroglou (AUTH/AHEPA)









HADRON THERAPY SYMPOSIUM

Questions for Aikaterini Tzantzaroudi (Hippokartion Hospital)










HADRON THERAPY SYMPOSIUM

Questions for Emmanouel Chatzipantelis (AUTH/AHEPA)










HADRON THERAPY SYMPOSIUM

Questions for Evgenia Papakonstantinou (Hippokration Hospital)









HADRON THERAPY SYMPOSIUM

Questions for Capizzello Antonio (AUTH/AHEPA), Eftychia Tataridou (Theageneio Hospital)



This project has received funding from the European Union's Harizon 2020 research and innovation programme under grant agreement No 101008548



www.hitriplus.eu



Questions for Barbara Rombi (APSS-TRENTO)







HADRON THERAPY SYMPOSIUM

Questions for George Giakoumetis (AUTH/AHEPA)





This project has received funding from the European Union's Harizon 2020 research and innovation programme under grant agreement No 101008548



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Semi Harrabi (HIT)







HADRON THERAPY SYMPOSIUM

Monday 21st octomber, 2024

Questions for Antonio Capizzello and Eytixia Tataridou(AUTH/AHEPA)









HADRON THERAPY SYMPOSIUM

Questions for George Giakoumetis (AUTH/AHEPA)







HADRON THERAPY

Questions fro Niklas Wahl (DKFZ)

1.Kayode A. DADA: Please can you repeat how to install matRad if one has matlab software already

installed

ANSWER:

2. Thandar Aung: When might the next release with Helium update come out?

ANSWER:

3. Thandar Aung: Does matRad allow for LET optimization?

ANSWER:

4.Mariana Brás: I didn't fully understand the dij matrix. Is it the optimal dose matrix in each patient voxel, which then the software tries to come as close as possible by adjusting the beamlets, or is it already the dose in each voxel due to the beamlets calculated previously?

ANSWER:

5.Luca Garolfi: is there any way to change the dimension of the beam cross-section? hoddid you plot the proton beamlet?

ANSWER:

6.Mariana Brás: Yes, is it possible to optimize the dose in a target for transmission protons beams, for example?

ANSWER:

7.Thandar Aung: I don't know if I missed it but what is the difference between LEM4 effect and LEM4 RBExD?

ANSWER:

8. Shelly: If there is robustness, when we optimized?

ANSWER:

9.panagiotis koliokitsos: until when we can submit our matrad images to attain a school certificate?

ANSWER: 10.Luca Garolfi: Could you expalin in a simple way why some "spikes" occur in the function optimisation plot?

ANSWER:

11. Shelly: Does the Matrad provide the LET calculation or optimization for proton and carbon?

ANSWER:

12. Thandar Aung: Why do we have only one alpha and beta value for each organ if we can have the same organ at different depths of the beam where the values will be different?

ANSWER:

13. Shelly: One more quick question, do your team consider the ARC in proton?

ANSWER:

14.Luca Garolfi: How do we get updatd about MatRad new releases and new features?

ANSWER:





This project has received funding from the European Union's Harizon 2020 research and innovation programme under grant agreement No 101008548



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM









HADRON THERAPY SYMPOSIUM

Questions for Athanasios Koutsostathis (NTUA)





This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101003548



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Niklas Wahl (DKFZ)





This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008548



www.hitriplus.eu

HADRON THERAPY SYMPOSIUM

Questions for Yiota Foka (GSI)









HADRON THERAPY SYMPOSIUM

Questions for Nermine Muradi (Uniiversity of Tetovo)









HADRON THERAPY SYMPOSIUM

Questions for Nicholas Sammut (Uni of Malta)